Concepedia

379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

Peter Schmid, Piotr J. Wysocki, Y.H. Park, Renan Fernandes, Simon Lord, Richard D. Baird, Catherine Prady, Kyung Hae Jung, Jamil Asselah, Robert Huisden,

Annals of Oncology · 2023 · 46 citations · 0 references

Open access

Concepts

MedicineOncologyPharmacologyBreast OncologyChemotherapyMetastasisAdjuvant TherapyBreast Cancer PharmacotherapyLocally Advanced Breast CancerMetastatic Breast CancerMetastatic Disease TreatmentTargeted Cancer TherapyBreast Cancer ChemotherapyDurvalumab TherapyMetastatic Breast Cancer TreatmentPhase Ii InvestigationTriple-negative Breast Cancer Therapy